Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy.


van Duin, Mark, Broyl, Annemiek, de Knegt, Yvonne, Goldschmidt, Hartmut, Richardson, Paul G, Hop, Wim C J, van der Holt, Bronno, Joseph-Pietras, Debora, Mulligan, George, Neuwirth, Rachel, Sahota, Surinder S. and Sonneveld, Pieter (2011) Cancer testis antigens in newly diagnosed and relapse multiple myeloma: prognostic markers and potential targets for immunotherapy. Haematologica, 96, (11), 1662-1669. (doi:10.3324/haematol.2010.037978). (PMID:21791470).

Download

Full text not available from this repository.

Description/Abstract

Relapsed multiple myeloma reveals extensive cancer testis antigen expression. Cancer testis antigens are confirmed as useful prognostic markers in newly diagnosed multiple myeloma patients and in relapsed multiple myeloma patients. The HOVON-65/GMMG-HD4 trial is registered under Dutch trial register n. NTR-213. CREST, SUMMIT and APEX trials were registered under ns. M34100-024, M34100-025 and NCT00049478/NCT00048230, respectively.

Item Type: Article
ISSNs: 0390-6078 (print)
1592-8721 (electronic)
Related URLs:
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Divisions: Faculty of Medicine > Cancer Sciences
ePrint ID: 339787
Date Deposited: 30 May 2012 13:16
Last Modified: 27 Mar 2014 20:22
URI: http://eprints.soton.ac.uk/id/eprint/339787

Actions (login required)

View Item View Item